Document text
Principal Investigator: Darrell J Irvine
Organization: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Fiscal Year: 2021
Award: $752,435
Funding agency: National Institute of Biomedical Imaging and Bioengineering
SpongeBot represents a new class of genetically modified cells to address the COVID-19 pandemic, leveraging
a novel antiviral platform developed under the proposer team’s existing NIH NIBIB R01 project. This antiviral
platform facilitates rapid, targeted SpongeBot development and deployment against SARS-CoV-2, its viral
mutations, as well as entirely new viruses - providing a barrier to future viral pandemics.
SARS-CoV-2 is highly communicable and individuals can transmit the disease even prior to becoming
symptomatic, sharply increasing the rate of disease spread. During the first two weeks following infection, the
innate immune system attempts to slow down the rapidly multiplying pathogen to provide time for the adaptive
immune system to develop more specific and effective mechanisms to destroy the virus. However, in individuals
with decreased or compromised immune responses, the excessive viral load can lead to elevated inflammation,
severe tissue damage, and ultimately death.
SpongeBot, our bioengineered cell-based therapy solution, provides vital support to the body’s immune system,
through its genetically designed ability to sequester and destroy SARS-CoV-2 viral particles at sites of injury, in
addition to attenuation of the immune system’s hyperinflammatory response to the virus. Administering
SpongeBot cells to an infected individual reduces and keeps viral load below dangerous thresholds, prevents
harmful hyperinflammation, and provides the adaptive immune system the time required to mount an effective
defense against the virus.
SpongeBot can be administered prophylactically to at-risk populations (e.g., healthcare workers, the elderly, or
immunocompromised individuals), or therapeutically at any stage during the course of viral infection. Importantly,
SpongeBot therapy is extremely safe; the base technology has a long proven clinical safety track record. Unlike
the lengthy development times necessary for vaccines or antiviral medications, a targeted SpongeBot therapy
against a predicted virus can be placed in clinical trials immediately. SpongeBot development for a novel virus
would be ready for deployment in only about 12 weeks.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><ACE2><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Adaptive Immune System><Address><Animal Model><Animal Models and Related Studies><Antibodies><Antibody-Dependent Enhancement><Antiviral Agents><Antiviral Drugs><Antivirals><Appearance><Assay><Attenuated><B-Cell Stimulatory Factor 1 Gene><BSF-1 Gene><BSF1 Gene><Bioassay><Biodistribution><Biologic Assays><Biological Assay><Biomedical Engineering><Body Tissues><Breakbone Fever Virus><CD126 Antigens><CD126 Receptor><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19><COVID-19 S protein><COVID-19 associated death><COVID-19 associated fatality><COVID-19 associated mortality><COVID-19 crisis><COVID-19 death><COVID-19 epidemic><COVID-19 fatality><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 induced death><COVID-19 induced fatality><COVID-19 induced mortality><COVID-19 infected patient><COVID-19 infection><COVID-19 mortality><COVID-19 pandemic><COVID-19 patient><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 related death><COVID-19 related fatality><COVID-19 related mortality><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 virus><COVID19><COVID19 S protein><COVID19 associated death><COVID19 associated fatality><COVID19 associated mortality><COVID19 crisis><COVID19 death><COVID19 epidemic><COVID19 fatality><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 induced death><COVID19 induced fatality><COVID19 induced mortality><COVID19 infection><COVID19 mortality><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 related death><COVID19 related fatality><COVID19 related mortality><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 virus><CSIF><CSIF-10><CV-19><CV19><Capsid><Cell Body><Cell Therapy><Cell membrane><Cells><Cells Placenta-Tissue><Cellular biology><Cessation of life><Chimera Protein><Chimeric Proteins><Clinical><Clinical Research><Clinical Study><Clinical Trials><CoV-2><CoV2><Common Rat Strains><Complex><Conserved Sequence><Custom><Cytokine Synthesis Inhibitory Factor><Cytoplasmic Membrane><DNA Molecular Biology><Dangerousness><Death><Dengue><Dengue Virus><Dengue fever virus><Development><Disease><Disorder><Distant><Drugs><Ebola><Economics><Elderly><Epithelial Cells><Epitheliasin Gene><Esteroproteases><Fusion Protein><Future><Genes><Genetic Alteration><Genetic Change><Genetic Engineering><Genetic Engineering Biotechnology><Genetic Engineering Molecular Biology><Genetic defect><Genome><Genomics><Grant><Guide RNA><HIV><Health><Health Care Providers><Health Personnel><Healthcare Providers><Healthcare worker><Human><Human Characteristics><Human Immunodeficiency Viruses><Human Nature><IL-10><IL-4 Gene><IL-6 Receptors><IL10><IL10A><IL4><IL4 gene><IL6 Receptors><Immune response><Immune system><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunological response><Immunology><Immunomodulation><Immunosuppressed Host><In Vitro><Individual><Infection><Inflammation><Inflammatory><Injury><Innate Immune System><Interleukin 10 Precursor><Interleukin 6 Receptor><Interleukin-10><Interleukin-4 Gene><Interleukin-4 Precursor Gene><Kinetics><LAV-HTLV-III><Lead><Libraries><Lung><Lung Respiratory System><Lymphadenopathy-Associated Virus><Lytotoxicity><MERS><MERS coronavirus disease><MERS-CoV disease><Measures><Medication><Mesenchymal Progenitor Cell><Mesenchymal Stem Cells><Mesenchymal progenitor><Mice><Mice Mammals><Micro RNA><MicroRNAs><Middle East Respiratory Syndrome><Middle East Respiratory Syndrome CoV disease><Middle East Respiratory Syndrome coronavirus disease><Middle Eastern Respiratory Syndrome><Middle Eastern Respiratory Syndrome CoV disease><Middle Eastern Respiratory Syndrome coronavirus disease><Modern Man><Molecular><Molecular Biology><Murine><Mus><Mutation><NIBIB><NIH><National Institute of Biomedical Imaging and Bioengineering><National Institutes of Health><Non-Polyadenylated RNA><Normal Placentoma><Organ><PRSS10><Pathogenicity><Pb element><Peptidases><Peptide Hydrolases><Pharmaceutic Preparations><Pharmaceutical Preparations><Placenta><Placenta Embryonic Tissue><Placentome><Plasma Membrane><Play><Populations at Risk><Protease Gene><Proteases><Proteinases><Proteins><Proteolytic Enzymes><RNA><RNA Gene Products><Rat><Rats Mammals><Rattus><Recombinant DNA Technology><Ribonucleic Acid><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 associated death><SARS-CoV-2 associated fatality><SARS-CoV-2 associated mortality><SARS-CoV-2 death><SARS-CoV-2 epidemic><SARS-CoV-2 fatality><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 induced death><SARS-CoV-2 induced fatality><SARS-CoV-2 induced mortality><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 mortality><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 related death><SARS-CoV-2 related fatality><SARS-CoV-2 related mortality><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Site><Source><System><Systems Biology><TMPRSS2><TMPRSS2 gene><Technology><Testing><Therapeutic><Time><TimeLine><Tissues><Treatment Efficacy><United States National Institutes of Health><Vaccination><Vaccines><Viral><Viral Burden><Viral Diseases><Viral Genome><Viral Load><Viral Load result><Virion><Virulent><Virus><Virus Diseases><Virus Particle><Virus-HIV><Vulnerable Populations><Wuhan coronavirus><acquired immune system><advanced age><allergic/immunologic body system><allergic/immunologic organ system><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral agents><anti-viral drugs><anti-virals><attenuation><authority><base><bio-engineered><bio-engineers><bioengineering><cell biology><cell engineering><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular engineering><cellular therapy><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 associated death><coronavirus disease 2019 associated fatality><coronavirus disease 2019 associated mortality><coronavirus disease 2019 crisis><coronavirus disease 2019 death><coronavirus disease 2019 epidemic><coronavirus disease 2019 fatality><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 induced death><coronavirus disease 2019 induced fatality><coronavirus disease 2019 induced mortality><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 mortality><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 related death><coronavirus disease 2019 related fatality><coronavirus disease 2019 related mortality><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus patient><cytokine><cytokine release syndrome><cytokine storm><cytotoxicity><death due to COVID-19><death due to COVID19><death due to SARS-CoV-2><death due to coronavirus disease 2019><death due to severe acute respiratory syndrome coronavirus 2><death in COVID><death in COVID-19><death in SARS-CoV-2><death in coronavirus disease><death in coronavirus disease 2019><death in severe acute respiratory syndrome coronavirus 2><design><designing><developmental><drug repurposing><drug/agent><elders><fatality due to COVID-19><fatality due to COVID19><fatality due to SARS-CoV-2><fatality due to coronavirus disease 2019><fatality due to severe acute respiratory syndrome coronavirus 2><gRNA><genetic element><genetically engineered><genetically engineered cells><genetically modified cells><genome mutation><geriatric><hCoV19><health care personnel><health care worker><health provider><health workforce><healthcare personnel><heavy metal Pb><heavy metal lead><host response><immune modulation><immune regulation><immune system response><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><immunosuppressed patient><in vivo><indexing><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><injuries><intervention efficacy><late life><later life><medical personnel><miRNA><miRNAs><model of animal><model organism><mortality><mortality due to COVID-19><mortality due to COVID19><mortality due to SARS-CoV-2><mortality due to coronavirus disease 2019><mortality due to severe acute respiratory syndrome coronavirus 2><mutant><nCoV2><neutralizing antibody><novel><novel virus><older adult><older person><overexpress><overexpression><pandemic><pandemic disease><particle><pathogen><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><plasmalemma><prevent><preventing><prophylactic><pulmonary><repurposing agent><repurposing medication><response><safety testing><senior citizen><severe acute respiratory syndrome coronavirus 2 associated death><severe acute respiratory syndrome coronavirus 2 associated fatality><severe acute respiratory syndrome coronavirus 2 associated mortality><severe acute respiratory syndrome coronavirus 2 death><severe acute respiratory syndrome coronavirus 2 fatality><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 induced death><severe acute respiratory syndrome coronavirus 2 induced fatality><severe acute respiratory syndrome coronavirus 2 induced mortality><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 mortality><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 related death><severe acute respiratory syndrome coronavirus 2 related fatality><severe acute respiratory syndrome coronavirus 2 related mortality><severe acute respiratory syndrome-CoV><synthetic biology><therapeutic efficacy><therapy efficacy><treatment provider><vaccine antibodies><vaccine induced antibodies><vaccine-induced antibodies><viral DNA><viral RNA><viral infection><virology><virus DNA><virus RNA><virus genome><virus infection><virus-induced disease><vulnerable group>